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ABSTRACT 
Excessive aggregation of proteins has a major impact on cell fate and is a hallmark of 
amyloid diseases in humans. To resolve insoluble deposits and to maintain protein 
homeostasis, all cells employ dedicated protein disaggregation, protein folding and 
protein degradation factors. Despite intense recent research, the underlying 
mechanisms controlling this key metabolic event are not well understood. Here, we 
have analyzed how a single factor, the highly conserved serine protease HTRA1, 
degrades amyloid fibrils in an ATP-independent manner. This PDZ-protease 
solubilizes protein fibrils and disintegrates the fibrillar core structure allowing 
productive interaction of aggregated polypeptides with the active site for rapid 
degradation. Thereby, aggregate burden in a cellular model of cytoplasmic tau 
aggregation is reduced. Mechanistic aspects of ATP-independent proteolysis and its 
implications in amyloid diseases are discussed. 
 
INTRODUCTION 
Misfolded polypeptides or protein fragments can associate into insoluble protein 
aggregates, e.g. inclusion bodies and amyloid fibrils. Inclusion bodies are commonly 
observed when overproducing recombinant proteins and are characterized by an 
amorphous surface1. Amyloids arising from native proteins or protein fragments 
comprise fibrils formed by ordered β-sheets that can also form helical filaments and 
are hallmarks of degenerative protein folding diseases
2
. 
To counteract the potential lethal effects of misfolded proteins and insoluble 
aggregates, protein quality control systems perform protein diagnosis, repair and 
degradation. Individual misfolded proteins are considered easier targets of protein 
 ͵
quality control compared to insoluble aggregates because the accessibility of the 
individual constituents of tightly packed amyloids is limited. Therefore, recent 
research has addressed the important question of protein disaggregation as a 
prerequisite of efficient protein repair and degradation. The most widely studied 
factors involved in protein disaggregation belong to the classic heat shock protein 
(Hsp) family
3
, members of which are chaperones and co-chaperones of the Hsp40, 70, 
90 and Hsp104 subclasses. Current data suggest a concerted cooperation of the 
Hsp40, 70 and Hsp104 (AAA
+
) chaperones in protein disaggregation with the final, 
ATP-fuelled threading of individual, unfolded substrate proteins through the central 
pore of Hsp104 being essential for disrupting the tight aggregate structure. 
Subsequently, these unfolded polypeptides are released for either refolding or 
proteolytic degradation (for review, see
4
). However, a single protein that is able to 
eliminate fibrillar aggregates and harbors both dissolving and proteolytic functions is 
unknown. 
Human HTRA1 belongs to the widely conserved family of high-temperature 
requirement A (HtrA) proteins that function as ATP-independent serine proteases in 
protein quality control and stress response pathways
5,6
. Individual HtrAs mediate 
sensing, repair and degradation of damaged, fragmented and mislocalized proteins. 
Defining features of HtrA proteases are their homooligomeric architecture and C-
terminal PDZ domains that preferentially bind to surface exposed tri- or tetrapeptide 
motifs. PDZ domains of HtrA proteases can be involved in sensing of misfolded 
proteins, substrate processing, allosteric and cooperative regulation of the proteolytic 
activity and in the switch between various oligomeric states (for review, see
6
).  
Ubiquitously expressed human HTRA1 consists of a signal sequence for secretion, a 
partial insulin like growth factor binding protein-7 (IGFBP-7) domain, a serine 
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protease domain and one C-terminal PDZ domain. Like all other HtrAs, HTRA1 
switches reversibly between active and inactive conformations. While the PDZ 
domain of HTRA1 has not been implicated in allosteric regulation, it contributes to 
substrate processing, as a PDZ deletion affects the length of cleavage products
7
. In 
addition, the PDZ domain binds specific interaction partners, which seems one way of 
regulating the subcellular location of HTRA1
8
. 
HTRA1 is found in three subcellular locations. Secreted HTRA1 is involved in the 
homeostasis of the extracellular matrix
9-14
 and intracellular HTRA1 was localized to 
the cytoplasm, to microtubules and to the nucleus
8,15,16
. Microtubule-associated 
HTRA1 degrades tubulins, thereby inhibiting cell migration
8,17
. Moreover, HTRA1 
has been implicated in several severe pathologies including cancer, age-related 
macular degeneration, Alzheimer's disease (AD), arthritis and familial ischemic 
cerebral small-vessel disease
10-12,18-22
. In these diseases, protein fragments or 
aggregates are either causative for disease or are disease modifying factors that are 
produced or degraded by HTRA1. 
The microtubule-associated protein tau aggregates into intracellular neurofibrillary 
tangles representing one hallmark of AD and other tauopathies. Normal tau is thought 
to regulate microtubule dynamics. Interaction of tau with microtubules is mediated by 
its microtubule binding domain (MTBD) composed of several pseudorepeats sharing 
the consensus sequence VxSKxGSxxN(L/I)xHxPGGG. Typically resulting from an 
abnormally high degree of phosphorylation, free tau protein mislocalizes to the 
somatodendritic compartment of neurons, where it polymerizes into straight or paired 
helical filaments (PHF), ribbons and other conformations. The core domain of PHFs 
consists of three or four repeats of MTBD mediating tau-tau interactions. In addition, 
proteolytic processing by e.g. caspases
23
 or lysosomal proteases
24
 of tau may drive 
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fibril assembly. The progressive growth of such aggregates by capturing further tau 
proteins contributes to cell death and therefore pathological features (for review 
see
25
).  
Recent studies suggest that several HtrAs act as protein quality control proteases that 
digest un- or misfolded proteins but not folded proteins (for review see
6
). In addition, 
HTRA1 degrades aggregated and fibrillar tau
26
. As substrate cleavage requires the 
precise positioning of an isolated peptide stretch to the proteolytic site, the local 
disruption of tight fibrillar interactions should be a prerequisite for efficient 
degradation. Here, we show that HTRA1 uses fibril disintegration as an integral 
aspect of its proteolytic activity towards amyloid fibrils and thus combines 
disintegration and protease activities in a single protein. Strikingly, the intrinsic 
disintegration activity of HTRA1 facilitates proteolysis of tau fibrils thereby reducing 
the aggregate burden in a cellular model of cytoplasmic tau aggregation.  
 
RESULTS 
HTRA1 disintegrates tau fibrils 
As HTRA1 digests tau fibrils
26
, we sought to identify a potential disintegration 
activity of HTRA1 that would improve proteolytic degradation of inaccessible 
substrates. To assay disintegration separately from proteolysis, we used the 
proteolytically inactive variant HTRA1 Ser328Ala for initial experiments. Fibrils of 
the 441 residue isoform (4R) of tau
26,27
 were incubated with or without equimolar 
amounts of HTRA1 S328A or the control protein aldolase. Disintegration, the product 
of which is soluble tau, was analyzed by sedimentation assays using 
ultracentrifugation. While incubation of fibrils with HTRA1 S328A yielded mainly 
soluble tau, incubation with aldolase had insignificant effects on the relative amount 
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of soluble tau (Fig. 1a, left panel and Supplementary Results, Supplementary Fig. 1a). 
Note that HTRA1 S328A and aldolase were almost completely soluble under the 
conditions tested (Fig. 1a, right panel). Moreover, a titration experiment revealed a 
dose-dependent effect on the solubilization of tau fibrils by HTRA1 S328A 
(Supplementary Fig. 1b).  
To investigate whether fibrils composed of the MTBD of tau are also solubilized, we 
repeated the sedimentation assays using a 3 fold molar excess of HTRA1 S328A. 
Note that these fibrils are packed more tightly compared to 4R tau fibrils
28
 and exhibit 
SDS-resistant tau dimers in SDS-PAGE (Supplementary Fig. 1c, top panel). Again, 
incubation of these fibrils with HTRA1 S328A led to soluble tau, while incubation 
with the control aldolase was ineffective (Supplementary Figures 1c, top panel and 
1d). In the absence of MTBD tau, HTRA1 and aldolase were in the soluble fraction, 
while HTRA1 S328A was both in the soluble and pellet fractions upon incubation 
with MTBD aggregates (Supplementary Fig. 1c, bottom panels). The reason for 
insoluble HTRA1 is unknown. Presumably, HTRA1 binds tightly to residual fibrils 
resistant to disintegration and is therefore co-sedimented during ultracentrifugation 
(Supplementary Fig. 1c, bottom left).  
 
Quantification via atomic force microscopy (AFM) 
To obtain independent and quantitative experimental evidence, disintegration was 
assessed by a single molecule approach. AFM of untreated samples revealed 
individual fibrillar structures of various lengths (0.1 up to >2 µm) and a characteristic 
width of around 20 – 25 nm as described
26,29
. AFM analyses were performed after 
incubation with or without equimolar amounts of HTRA1 S328A (Fig. 1b) or the 
isolated PDZ domain of HTRA1 as a control (Fig. 1c). For quantification of fibril 
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abundance in each sample, the lengths of individual fibrils were measured and added 
up to obtain a value of total fibril length. Comparison of these data indicated that 
incubation with HTRA1 S328A caused a statistically significant, 4 fold reduction of 
the amount of fibrils, whereas incubation with the PDZ domain alone did not 
(Supplementary Fig. 2a,b). Also, assessment of the distribution of fibril size revealed 
that disintegration was independent of their length (Supplementary Fig. 2c), 
indicating that no subset of fibrils was preferentially disintegrated or resistant to 
disintegration. 
 
Internalization of recombinant HTRA1 by cultured cells 
Subsequently, we examined whether disintegration of fibrils occurs in living cells. We 
established cellular tau aggregation and an alternative approach of introducing 
defined amounts of HTRA1 into human cells, i.e. uptake of purified recombinant 
protein from the cell culture medium without protein transfection reagents 
(Supplementary Fig. 3a,b). This method excludes problems arising from plasmid 
transfection i.e. heterogeneity and uncontrolled protein levels within a batch of cells. 
Importantly, confocal microscopy revealed colocalization of internalized HTRA1 
S328A with both its native cytosolic substrate tau and endogenous HTRA1 
(Supplementary Fig. 3c,d). The secondary antibody control did not show any signal 
with the respective settings (Supplementary Fig. 3e). 
 
Disintegration of intracellular tau fibrils 
Aggregation of cytoplasmic tau in 293T HEK cells (transiently overexpressing HA-
tagged tau) was induced by seeding with fragmented MTBD fibrils
30
. Staining of cells 
with the amyloid specific fluorescent dye Thioflavin S (ThS) and immunostaining of 
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tau show that cells were loaded with aggregated tau (Fig. 2a). In addition, distinct 
colocalization of HTRA1 and tau fibrils was observed in cells treated with 
recombinant HTRA1 S328A (Fig. 2b, arrowheads). 
Subsequently, we tested the effect of HTRA1 S328A on aggregated tau levels (Fig. 
2c). Cells containing tau fibrils were treated with recombinant HTRA1 S328A and 
incubated for 20 h, followed by sarkosyl extraction of cell lysates. Pellet fractions 
from this extraction contain tau aggregates whereas supernatants contain soluble tau. 
These fractions were subjected to Western blotting using antibodies against tau and 
HTRA1.  Quantification of band intensities revealed a significant and about 3 fold 
lower amount in sarkosyl insoluble tau in HTRA1 S328A treated cells compared to 
the PBS control (Fig 2c, middle panel and Supplementary Fig. 4a), while there were 
no marked differences in soluble tau levels (Fig. 2c, left panel).   
 
Disintegration enhances proteolysis of tau fibrils  
Fibril disintegration by HTRA1 should improve the accessibility of individual tau 
polypeptides to the active site, thus allowing enhanced proteolysis. To test this model, 
we established experimental conditions to measure the effects of disintegration on 
proteolytic digestion. This approach combines pre-treatment of fibrils with HTRA1 
S328A before adding low amounts of proteolytically active HTRA1. Therefore, 
purified tau fibrils were preincubated with HTRA1 S328A for 2 h and subsequently 
incubated with proteolytically active HTRA1 (Fig. 3a, right panel). Indeed, fibrillar 
tau was more efficiently digested following preincubation with HTRA1 S328A 
compared to preincubation with buffer or PDZ domain controls (Fig. 3a, left and 
lower panel, respectively). Moreover, HTRA1's disintegration activity should not lead 
to improved processing of soluble tau because it is an unstructured substrate
31
. As 
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expected, soluble tau was not digested more rapidly following preincubation with 
HTRA1 S328A (Fig. 3b). In contrast, the presence of HTRA1 S328A led to slightly 
slower digestion of soluble tau, probably because of competitive binding to tau. 
To obtain additional evidence for the model that disintegration activity acts mainly on 
fibrils, we incubated fibrillar and soluble tau with a 10 fold higher concentration of 
proteolytically active HTRA1 (Supplementary Fig 5a). At these increased levels, 
active HTRA1 is able to efficiently perform both disintegration and proteolysis. 
Clearly, higher protease concentrations strongly improved the digestion of fibrils 
(compare left panels of Fig. 3a and Supplementary Fig. 5a) but not of soluble tau 
(compare left panel of Fig. 3b and right panel of Supplementary Fig. 5a).  
Using the cellular model of tau aggregation (Fig. 2), we asked whether added 
proteolytically active HTRA1 would reduce the levels of aggregated tau. Cells 
containing seeded tau aggregates were treated with recombinant HTRA1 or PBS for 
20 h. Subsequently, sarkosyl extraction of cell lysates yielded pellet fractions 
containing aggregates and supernatants containing soluble tau. As expected, cells 
treated with HTRA1 had ca. 6 fold less tau aggregates as compared to the PBS 
controls (Supplementary Fig. 4b, top and bottom right panels). While the levels of 
soluble tau were reduced in HTRA1 treated cells that were not seeded with fibril 
fragments, in agreement with previously published data
26
, there were no marked 
differences of soluble tau levels in cells treated with seeds (Supplementary Fig. 4b, 
left panel). The latter might be explained by a preference of HTRA1 for fibrils 
compared to soluble tau, as suggested above.  
 
Quantification of proteolysis following disintegration 
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To quantify improved proteolytic processing of tau fibrils, the protease assays 
described (Fig. 3a,b) were repeated and samples were analyzed by AFM. Fibrillar tau 
was either preincubated with HTRA1 S328A or controls (buffer or PDZ domain of 
HTRA1) for 2 h, followed by incubation with active HTRA1 (Fig. 3c, Supplementary 
Fig. 5b). Quantification of fibril degradation was done as before (Supplementary Fig. 
2a,b). Digestion with HTRA1 alone or digestion following incubation with HTRA1's 
PDZ domain caused an about 2 fold reduction of fibrils. Notably, preincubation with 
HTRA1 S328A followed by incubation with active HTRA1 caused a statistically 
highly significant, 6 fold reduction in the amount of fibrils (Fig. 3c). Moreover, 
assessment of the distribution of fibril size revealed that disintegration occurred 
independently of their length (Supplementary Fig. 5c) corresponding to the analyses 
after disintegration only (Supplementary Fig. 2c). 
 
Mechanism of degradation of tau fibrils 
Single molecule analyses of fibrils were performed to further explore the mechanism 
of proteolysis. Fibril disintegration and proteolysis could either be a directional 
process initiated at the free ends of fibrils or involve the action of HTRA1 along the 
whole fibril length. To directly visualize the binding of HTRA1 to fibrils, negative-
stain electron microscopy (EM) was employed. Fibrils incubated with equimolar 
amounts HTRA1 S328A prior to their isolation and negative staining clearly showed 
a regular decoration along each fibril (Fig. 4a, (B)) while buffer treated fibrils did not 
(Fig. 4a, (A)). This decoration was even more pronounced when increasing the ratio 
of HTRA1:tau (Fig. 4a, (C)), although under these conditions HTRA1 seemed to 
occasionally dissociate from the fibrils, as seen from the sporadic single particles in 
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the background. Notably, the fibrils decorated with HTRA1 had a larger diameter 
than those without bound HTRA1 (Fig. 4a, inlets).  
Total internal reflection fluorescence microscopy (TIRFM) allowed us to directly 
observe the degradation of fluorescently labeled tau fibrils during incubation with 
active HTRA1 in real time (Fig. 4b,c, Supplementary Fig. 6). In accordance with the 
EM data (Fig. 4a), the fluorescence decreased across the entire length of the fibrils, 
rather than starting from the fibril ends, suggesting that proteolysis is not directional. 
This conclusion was supported by determining the relative decrease of fluorescence 
along the fibrils (Supplementary Fig. 6a). 
Quantification of fibril degradation during 10 h incubation showed a 68% decrease in 
fluorescence in the presence of HTRA1 compared to 29% in the buffer control, the 
latter being the result of bleaching (Supplementary Fig. 6b). Also, images of single 
endpoints, i.e. in the absence of repeated exposures and thus photobleaching, revealed 
decreased fluorescence of fibrils compared to buffer control (Supplementary Fig. 6c). 
Similar data were obtained at high temporal resolution during 4 h incubation even 
though the buffer control showed considerable effects of bleaching (Supplementary 
Video 1 and 2). HTRA1 degrades labeled fibrils as assessed by SDS-PAGE 
underlining that TIRFM data reflect degradation rather than removal of label (data not 
shown).  
To obtain further insights into how the intrinsic disintegration activity of HTRA1 
contributes to proteolysis, the occurrence of proteolytic products was followed over 
time. Fibrils were preincubated with HTRA1 S328A and subsequently incubated with 
active HTRA1 for various times or preincubated with buffer as a control (Fig. 5, 
green and orange bars, respectively). Peptidic products identified by mass 
spectrometry were mapped to sections of the primary amino acid sequence of tau. 
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After 3 h digestion, fibrils preincubated with or without HTRA1 S328A had 10 cuts in 
the tightly packed core region and 16 cuts in non-core regions versus no cuts in core 
and 3 cuts in non-core regions, respectively (Fig. 5a left panel). Even after overnight 
digestion without preincubation, HTRA1 performed only 2 cuts within the core region 
(Fig. 5a right panel). Overall in the o/n samples, proteolytic processing lead to a total 
of 34 vs. 10 cuts with and without preincubation, respectively (Fig. 5a right panel). 
Differences in digestion of soluble tau were less pronounced as soluble tau was also 
cleaved within the core region without preincubation with HTRA1 S328A, as 
expected (Fig. 5b).  
The mass spectrometry data indicate that, without preincubation with HTRA1 S328A, 
HTRA1 initiates processing of fibrils from the less tightly packed N- and C-termini, 
of tau proceeding into the core regions only at later time points, probably once the 
core regions were destabilized by disintegration or the initial cuts. Critically, the 
disintegration activity of HTRA1 significantly enhances the immediate proteolytic 
processing of tightly packed regions of fibrils leading to an overall more efficient 
degradation.  
To obtain further direct and independent experimental evidence of binding of specific 
tau sequences to HTRA1, peptides were synthesized corresponding to various regions 
of tau. The dissociation constants (KD) for binding to HTRA1 were measured by 
isothermal titration calorimetry (ITC) (Supplementary Fig. 7). Peptides corresponding 
to residues 298-309 in the repeat region exhibited a KD of 25 µM, while peptides 
corresponding to residues 385-393 or 385-399 had KDs of 35 µM and 40 µM, 
respectively. Peptides corresponding to residues 247-256 and 402-417 did not bind to 
HTRA1. These data reveal sequence specificity of the interaction of tau with HTRA1 
and thus of disintegration and proteolysis. 
 ͳ͵
 
Role of HTRA1's PDZ domain in fibril disintegration 
Binding of peptides to the PDZ domains of HtrA proteases has been implicated in 
substrate binding, allosteric regulation and subcellular location. Therefore, we 
reasoned that the PDZ domain might contribute to fibril disintegration. To test this 
assumption, an HTRA1 S328A ∆PDZ construct was purified and its ability to 
disintegrate fibrils was assessed by sedimentation, AFM, preincubation in 
combination with subsequent protease assays, mass-spectrometric analysis of 
cleavage products, and in cell-based assays of tau aggregation (Fig. 6a-e).  
Neither HTRA1 S328A ∆PDZ, nor the isolated PDZ domain was able to solubilize 
fibrils composed of full-length tau (Fig. 6a, Supplementary Fig. 8a) or MTBD tau 
(Supplementary Fig. 8c,d) in sedimentation assays and AFM analyses (Fig. 6b, 1c, 
Supplementary Fig. 8b). While HTRA1 S328A remained in the supernatant after 
ultracentrifugation, HTRA1 ∆PDZ S328A was found in the pellet after incubation 
with full-length or MTBD tau fibrils. As HTRA1 ∆PDZ S328A was soluble after 
incubation in the disintegration buffer (Supplementary Fig. 8a, c lower panels), this 
was not due to buffer induced precipitation. More likely, HTRA1 ∆PDZ S328A binds 
to and co-sediments with fibrils.  
Proteolysis of fibrils by HTRA1 was only slightly enhanced by preincubation with 
HTRA1 S328A ∆PDZ (Fig. 6c). Note, that in the presence of high concentrations of 
HTRA1 S328A proteolytic products appear with an apparent molecular mass of ca. 
25 kDa, possibly due to proteolysis of HTRA1 S328A by HTRA1 (Fig. 6c, asterisk). 
According to the minor effect of HTRA1 ∆PDZ S328A detected by SDS-PAGE, mass 
spectrometry revealed that proteolytic cleavage of the tightly packed fibril core was 
enhanced by preincubation with HTRA1 S328A ∆PDZ to a lesser extent compared to 
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preincubation with HTRA1 S328A (Fig. 6d). While preincubation with HTRA1 
S328A increased the number of cleavage sites significantly in core sections E, F and 
G, preincubation with HTRA1 ∆PDZ S328A increased the number of cleavage sites 
in section E only. Changes in the number of cleavage sites in soluble tau were only 
significant in one, non-core segment of tau (for a detailed list of p-values, see 
Supplementary Table 1).   
Using the cellular model of tau aggregation (Fig. 2), we compared the effects of 
added HTRA1 ∆PDZ S328A with HTRA1 S328A. As expected, deletion of the PDZ 
domain of HTRA1 reduced HTRA1's ability to lower the aggregate burden as the 
amounts of sarkosyl insoluble tau detected in cells treated with HTRA1 ∆PDZ S328A 
was not significantly reduced compared to the PBS control. Accordingly, the 
differences between HTRA1 S328A and HTRA1 ∆PDZ S328A and between HTRA1 
S328A and PBS control were statistically significant (Supplementary Fig. 8e). 
Moreover, ITC measurements using the tau derived peptide KTDHGAEIV (aa 385-
393) failed to detect binding to HTRA1 lacking the PDZ domain (Fig. 6f, middle 
panel), while binding to the isolated PDZ domain occurred with a KD of 50.5 µM 
(Fig. 6f, left panel) i.e. with similar affinity compared to wt HTRA1 (Supplementary 
Fig. 7). Taken together, these data indicate that fibril disintegration is impaired but 
not completely abolished upon PDZ domain deletion, and even though the PDZ 
domain binds to tau peptides, it needs to be tethered to the protease domain to 
contribute to fibril disintegration.  
 
Disintegration of amyloidogenic Aβ1-42 aggregates 
The combination of disintegration and protease activities in HTRA1 could represent a 
general mechanism allowing cells to tackle other amyloid aggregates as well. To 
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initially test this model, aggregates of the amyloidogenic Aβ1-42 peptide were 
prepared in vitro
32
 and incubated with HTRA1 S328A or the control protein MDH, 
followed by sedimentation assays. As seen with tau fibrils (Fig. 1), incubation with 
HTRA1 S328A led to soluble Aβ1-42 peptides whereas incubation with MDH did not 
(Supplementary Fig. 9). Note that degradation of Aβ aggregates by HTRA1 has been 
reported previously
20
. 
 
DISCUSSION 
We report detailed insights into the mechanism of fibril proteolysis by HTRA1. This 
conserved protein quality factor has evolved an intrinsic ability, termed disintegration, 
to destabilize the tightly packed aggregate core to make it accessible to the proteolytic 
site. The proteolytic mechanism comprises the combined activity of disintegration and 
peptide bond hydrolysis and thereby ensures efficient degradation of tightly packed 
fibrils by a single protein quality control factor.  
The effect of disintegration by HTRA1 is specific for fibrillar tau because proteolytic 
degradation of soluble tau is not improved. This excludes substrate independent 
effects of proteolytically inactive HTRA1, and underlines the challenge imposed by 
aggregates on the protease for efficient degradation, which is overcome by 
disintegration. Interestingly, a 10 fold increase of the concentration of active HTRA1 
does not affect degradation of soluble tau while fibrils are degraded even faster than 
soluble tau. This points at distinct enzymatic states and conformation-specific 
recognition of substrates. This curious observation requires further studies to elucidate 
the underlying mechanism. 
Further specificity exists on the level of primary amino acid sequence as ITC data 
indicate that not every tau peptide is bound with the same affinity to HTRA1. This 
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result is based on sequence specific binding pockets of the protease and the PDZ 
domains of HtrA proteases
33-36
. It is also well established that both, protease and PDZ 
domains bind substrates in β-strand conformation7,33, making these sites suitable 
docking platforms for fibrils that are rich in β-strands. As the PDZ domain is tethered 
to the protease domain of HTRA1 via a flexible peptide linker it might be 
instrumental in destabilizing tightly packed fibrils by providing HTRA1 with a 
flexible substrate binding module distant from the active site. Indeed, all 
disintegration assays showed that deletion of this domain severely impaired the 
destabilization of tau fibrils in vitro and in cultured cells. The N-terminal domain of 
HTRA1 was not included in our analyses as biochemical and structural studies 
suggested it "has no apparent effect on protease activity, and in accordance with the 
structure-based predictions, neither the IGFBP nor Kazal-like module retains the 
function of their prototype proteins"
37
. Moreover, a recent report shows that the N-
terminus contributes to increased autoproteolysis under reducing conditions and that 
the autolytic forms display similar activity compared to full-length HTRA1
38
. 
The proteolytic mechanism of HTRA1 towards fibrils is a specific protein quality 
control function that is initiated along the entire length of amyloid fibrils, comprises 
disintegration of tightly packed regions, which is enhanced by the binding of specific 
sequences by the C-terminal PDZ domain, and ultimately results in the efficient 
proteolytic removal of amyloid fibrils. The latter step ensures unidirectionality of this 
process, as proteolytic processing by the same factor eliminates the need of releasing 
bound substrate, which is ATP dependent in classic chaperonins. Also, proteolysis 
generates short peptides with a presumably lower affinity to peptide binding sites, 
therefore allowing dissociation of ligands from HTRA1 in an ATP-independent 
manner. ATP-independent disaggregation was reported in other systems e.g. the 38-
 ͳ͹
kDa subunit of the multiprotein chloroplast signal recognition particle reverses 
aggregation of secretory proteins
39
. Interestingly, here, substrates are not proteolyzed 
but removed from the equilibrium by secretion into a different cellular compartment. 
The composite mechanism of fibril proteolysis expands the repertoire of HtrA 
functions. It has been previously established that the combination of protein refolding 
and degradation is occurring within single HtrA proteins
40-42
. It is therefore not 
surprising that some HtrA proteases have disintegration activity as well. Moreover, 
various functions of the PDZ domain have been characterized in detail, illustrating the 
evolutionary plasticity of individual domains and regulatory mechanisms within a 
protein family. The evolution of a mechanism specifically targeting amyloid fibrils 
including a role of the PDZ domain in disintegrating aggregates contribute to the 
versatility of HtrA proteins in protein quality control.  
Molecular chaperones and conformation specific proteases are key elements of 
protein quality control pathways that mediate cellular responses against amyloid 
accumulation, a hallmark of various neurological disorders. Indeed, HSP70 and 
HSP90 were shown to counteract tau accumulation and neurodegeneration in disease 
models
43
 perhaps by keeping tau soluble
44
 and HSP104 was shown solubilize tau 
fibrils in the test tube
45
. In addition to dedicated chaperones, several proteases are 
involved in tau degradation including calpain and the proteasome, although the latter 
can be overwhelmed or inhibited by tau fibrils (for review see
46,47
). In contrast to 
these factors, HTRA1 employs a unique mechanism of proteolysis including the 
combination of two functions in one protein, i.e. disintegration and hydrolysis, 
providing a novel mechanism of counteracting protein aggregation in an ATP-
independent manner. As HTRA1 dissolves Aβ1-42 aggregates as well, its 
disintegration activity might have wider implications. This notion is supported by 
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previous studies describing an association of HTRA1 with various amyloids
20,48
. 
Moreover, we show here that HTRA1 is internalized by cells from the medium, which 
might allow its distribution into areas of tissues that have low levels of this protein 
quality control factor. This feature might even contribute to a delay of onset of folding 
diseases such as AD. In addition, extracellular HTRA1 could degrade extracellular 
amyloids and might thus contribute to limited spreading of tau aggregation across 
brain regions which has been shown to proceed in a prion-like manner
49
. Additional 
experimental evidence supporting the potential implications of HTRA1 in AD 
includes the degradation of extracellular Aβ peptides20, its upregulation in an AD 
mouse model involving the overproduced Swedish variant of amyloid precursor 
protein
50
 and the inverse correlation of pathological tau and HTRA1 levels in patient 
brains
26
. Therefore, future work on HTRA1 is likely to contribute to a deeper 
mechanistic and functional understanding of the various strategies nature has evolved 
to counteract protein misfolding and aggregation to ultimately delay the onset of 
protein folding diseases. 
 
ACKNOWLEDGEMENTS 
We thank Nina Schulze and Melanie Graessl for help with TIRFM, Daniel Grum and 
Melisa Merdanovic with ITC, Svenja Blaskowski with mass spectrometry and Vanda 
Lux for providing purified PDZ domain and Maike Breiden for providing tau. This 
work was supported by grants EH 100/14-1 (to M.E.) and SFB 1093 (to M.E., M.K. 
and B.S.) and INST 20876/127-1 FUGG (to M.K.) from Deutsche 
Forschungsgemeinschaft. The IMP is funded by Boehringer Ingelheim. 
 
 ͳͻ
AUTHOR CONTRIBUTIONS 
S.P., designed and carried out experiments, analyzed data and wrote the paper; A.S 
and B.S. carried out AFM; F.K. and M.K., carried out mass spectrometry; C.G. and 
S.R. carried out EM; T.C., performed biochemistry; M.E., outlined the work and 
wrote the paper.  
  
 ʹͲ
REFERENCES 
1. Wang, L. Towards revealing the structure of bacterial inclusion bodies. Prion 
3, 139-145 (2009). 
2. Friedman, R. Aggregation of amyloids in a cellular context: modelling and 
experiment. Biochem J. 438, 415-426 (2011). 
3. Akerfelt, M., Morimoto, R.I. & Sistonen, L. Heat shock factors: integrators of 
cell stress, development and lifespan. Nat. Rev. Mol. Cell Biol. 11, 545-555 
(2010). 
4. Saibil, H. Chaperone machines for protein folding, unfolding and 
disaggregation. Nat. Rev. Mol. Cell Biol. 14, 630-642 (2013). 
5. Clausen, T., Southan, C. & Ehrmann, M. The HtrA family of proteases. 
Implications for protein composition and cell fate. Mol. Cell 10, 443-455 
(2002). 
6. Clausen, T., Kaiser, M., Huber, R. & Ehrmann, M. HTRA proteases: regulated 
proteolysis in protein quality control. Nat. Rev. Mol. Cell Biol. 12, 152-162 
(2011). 
7. Truebestein, L. et al. Substrate-induced remodeling of the active site regulates 
human HTRA1 activity. Nat. Struct. Mol. Biol. 18, 386-388 (2011). 
8. Chien, J. et al. Serine protease HtrA1 associates with microtubules and 
inhibits cell migration. Mol. Cell Biol. 29, 4177-4187 (2009). 
9. Tiaden, A.N. & Richards, P.J. The emerging roles of HTRA1 in 
musculoskeletal disease. Am. J. Pathol. 182, 1482-1488 (2013). 
10. Jones, A. et al. Increased expression of multifunctional serine protease, 
HTRA1, in retinal pigment epithelium induces polypoidal choroidal 
vasculopathy in mice. Proc. Natl. Acad. Sci. USA 108, 14578-14583 (2011). 
11. Vierkotten, S., Muether, P.S. & Fauser, S. Overexpression of HTRA1 leads to 
ultrastructural changes in the elastic layer of Bruch's membrane via cleavage 
of extracellular matrix components. PLoS ONE 6, e22959 (2011). 
12. Grau, S. et al. The role of human HtrA1 in arthritic disease. J. Biol. Chem. 
281, 6124-6129 (2006). 
13. Tsuchiya, A. et al. Expression of mouse HtrA1 serine protease in normal bone 
and cartilage and its upregulation in joint cartilage damaged by experimental 
arthritis. Bone 37, 323-336 (2005). 
14. Chamberland, A. et al. Identification of a novel HtrA1-susceptible cleavage 
site in human aggrecan: evidence for the involvement of HtrA1 in aggrecan 
proteolysis in vivo. J. Biol. Chem. 284, 27352-27359 (2009). 
15. Campioni, M. et al. The Serine Protease HtrA1 Specifically Interacts and 
Degrades the Tuberous Sclerosis Complex 2 Protein. Mol. Cancer Res. 8, 
1248-1260 (2010). 
16. Clawson, G.A., Bui, V., Xin, P., Wang, N. & Pan, W. Intracellular localization 
of the tumor suppressor HtrA1/Prss11 and its association with HPV16 E6 and 
E7 proteins. J. Cell. Biochem. 105, 81-88 (2008). 
17. Chien, J., He, X. & Shridhar, V. Identification of tubulins as substrates of 
serine protease HtrA1 by mixture-based oriented peptide library screening. J. 
Cell. Biochem. 107, 253-263 (2009). 
18. Chien, J., Campioni, M., Shridhar, V. & Baldi, A. HtrA serine proteases as 
potential therapeutic targets in cancer. Curr. Cancer Drug Targets 9, 451-468 
(2009). 
 ʹͳ
19. Yang, Z. et al. A variant of the HTRA1 gene increases susceptibility to age-
related macular degeneration. Science 314, 992-993 (2006). 
20. Grau, S. et al. Implications of the serine protease HtrA1 in amyloid precursor 
protein processing. Proc. Natl. Acad. Sci. USA 102, 6021-6026 (2005). 
21. Milner, J.M., Patel, A. & Rowan, A.D. Emerging roles of serine proteinases in 
tissue turnover in arthritis. Arthritis Rheum. 58, 3644-3656 (2008). 
22. Hara, K. et al. Association of HTRA1 mutations and familial ischemic 
cerebral small-vessel disease. N. Engl. J. Med. 360, 1729-1739 (2009). 
23. Gamblin, T.C. et al. Caspase cleavage of tau: linking amyloid and 
neurofibrillary tangles in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 100, 
10032-10037 (2003). 
24. Wang, Y.P., Biernat, J., Pickhardt, M., Mandelkow, E. & Mandelkow, E.M. 
Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like 
aggregation of full-length tau in a neuronal cell model. Proc. Natl. Acad. Sci. 
USA 104, 10252-10257 (2007). 
25. Spillantini, M.G. & Goedert, M. Tau pathology and neurodegeneration. Lancet 
Neurol. 12, 609-622 (2013). 
26. Tennstaedt, A. et al. Human High Temperature Requirement Serine Protease 
A1 (HTRA1) Degrades Tau Protein Aggregates. J. Biol. Chem. 287, 20931-
20941 (2012). 
27. Li, W. & Lee, V.M. Characterization of two VQIXXK motifs for tau 
fibrillization in vitro. Biochemistry 45, 15692-15701 (2006). 
28. Bibow, S. et al. The dynamic structure of filamentous tau. Angew. Chem. Int. 
Ed. Engl. 50, 11520-11524 (2011). 
29. Crowther, R.A. Straight and paired helical filaments in Alzheimer disease 
have a common structural unit. Proc. Natl. Acad. Sci. USA 88, 2288-2292 
(1991). 
30. Guo, J.L. & Lee, V.M. Seeding of normal Tau by pathological Tau 
conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 286, 
15317-15331 (2011). 
31. Mukrasch, M.D. et al. Structural polymorphism of 441-residue tau at single 
residue resolution. PLoS Biol. 7, e34 (2009). 
32. Kuperstein, I. et al. Neurotoxicity of Alzheimer's disease Abeta peptides is 
induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J. 29, 3408-
3420 (2010). 
33. Wilken, C., Kitzing, K., Kurzbauer, R., Ehrmann, M. & Clausen, T. Crystal 
structure of the DegS stress sensor: How a PDZ domain recognizes misfolded 
protein and activates a protease domain. Cell 117, 483-494 (2004). 
34. Krojer, T. et al. Interplay of PDZ and protease domain of DegP ensures 
efficient elimination of misfolded proteins. Proc. Natl. Acad. Sci. USA 105, 
7702-7707 (2008). 
35. Meltzer, M. et al. Allosteric activation of HtrA protease DegP by stress signals 
during bacterial protein quality control. Angew. Chem. Int. Ed. Engl. 47, 1332-
1334 (2008). 
36. Merdanovic, M. et al. Determinants of structural and functional plasticity of a 
widely conserved protease chaperone complex. Nat. Struct. Mol. Biol. 17, 
837-843 (2010). 
37. Eigenbrot, C. et al. Structural and functional analysis of HtrA1 and its 
subdomains. Structure 20, 1040-1050 (2012). 
 ʹʹ
38. Risor, M.W. et al. The autolysis of human HtrA1 is governed by the redox 
state of its N-terminal domain. Biochemistry 53, 3851-3857 (2014). 
39. Jaru-Ampornpan, P. et al. ATP-independent reversal of a membrane protein 
aggregate by a chloroplast SRP subunit. Nat. Struct. Mol. Biol. 17, 696-702 
(2010). 
40. Spiess, C., Beil, A. & Ehrmann, M. A temperature-dependent switch from 
chaperone to protease in a widely conserved heat shock protein. Cell 97, 339-
347 (1999). 
41. Krojer, T. et al. Structural basis for the regulated protease and chaperone 
function of DegP. Nature 453, 885-890 (2008). 
42. Malet, H. et al. Binding of substrate proteins inside the molecular cage of the 
chaperone-protease DegQ. Nat. Struct. Mol. Biol. 19, 152-157 (2012). 
43. Miyata, Y., Koren, J., Kiray, J., Dickey, C.A. & Gestwicki, J.E. Molecular 
chaperones and regulation of tau quality control: strategies for drug discovery 
in tauopathies. Future Med. Chem. 3, 1523-1537 (2011). 
44. Dou, F. et al. Chaperones increase association of tau protein with 
microtubules. Proc. Natl. Acad. Sci. USA 100, 721-726 (2003). 
45. DeSantis, M.E. et al. Operational plasticity enables hsp104 to disaggregate 
diverse amyloid and nonamyloid clients. Cell 151, 778-793 (2012). 
46. Johnson, G.V. Tau phosphorylation and proteolysis: insights and perspectives. 
J. Alzheimers Dis. 9, 243-250 (2006). 
47. Hegde, A.N. & Upadhya, S.C. Role of ubiquitin-proteasome-mediated 
proteolysis in nervous system disease. Biochim. Biophys. Acta 1809, 128-140 
(2011). 
48. Karring, H. et al. Composition and proteolytic processing of corneal deposits 
associated with mutations in the TGFBI gene. Exp. Eye Res. 96, 163-170 
(2012). 
49. Hardy, J. & Revesz, T. The spread of neurodegenerative disease. N. Engl. J. 
Med. 366, 2126-2128 (2012). 
50. Searcy, J.L., Le Bihan, T., Salvadores, N., McCulloch, J. & Horsburgh, K. 
Impact of age on the cerebrovascular proteomes of wild-type and Tg-SwDI 
mice. PLoS One 9, e89970 (2014). 
 
 
  
 ʹ͵
 
FIGURE LEGENDS 
Figure 1 
Disintegration of tau Fibrils by HTRA1 S328A. (a) Sedimentation assay of tau fibrils.  
Left panel: 4R tau fibrils were incubated with equimolar amounts of proteolytically 
inactive HTRA1 S328A (HTRA1 SA) or aldolase control followed by 
ultracentrifugation. Subsequently, samples before centrifugation (T, total), of pellet 
(P) and supernatant (S) fractions were subjected to SDS-PAGE and Coomassie 
staining. Right panel: SDS-PAGE of proteins incubated without tau. Uncropped gel 
images are provided in a Supplementary Data File. (b, c) AFM of 4R tau fibrils. To 
measure disintegration, fibrillar tau was incubated with equimolar amounts of (b) 
HTRA1 S328A or (c) the PDZ domain of HTRA1 as in (a) followed by AFM. 
Representative images are shown. Scale bar, 0.5 µm.  For quantification of fibril 
disintegration, see Supplementary Fig. 1 and 2. 
 
Figure 2  
Cell culture model of tau aggregation and sarkosyl extraction of HA-tagged tau. (a) 
Aggregation of cytoplasmic tau was induced by seeding with MTBD fibrils in 293T 
HEK cells transiently overexpressing HA-tagged P301L tau. Fixed cells were stained 
with the amyloid specific fluorescent dye Thioflavin S (ThS, green) and 
immunostained against the HA tag of overexpressed tau (αHA, red). (b) Cells 
containing seeded tau filaments were treated with AlexaFluor 568 labeled HTRA1 
S328A (1.35 µM) or the dye alone (both shown in red) followed by ThS staining 
(green) and ToPro3 nuclear counterstaining (blue). Arrowheads indicate regions of 
distinct colocalization of labeled HTRA1 and tau aggregates. Scale bars, 10 µm. (c) 
 ʹͶ
Cells treated with PBS or seeded with MTBD fibrils were treated with recombinant 
HTRA1 S328A (4.1 µM) or PBS for 20 h. Lysates were sarkosyl extracted to assess 
the amounts of soluble (left panel) versus aggregated (middle panel) tau using α tau 
antibodies. Sarkosyl soluble fractions were also immunoblotted against HTRA1 to 
show internalization of recombinant HTRA1 (right panel). Actin levels are loading 
controls or show that sarkosyl pellets did not contain cytoplasmic proteins (middle 
panel). Recombinant HTRA1 migrates at 37 kDa and native HTRA1 at 51 kDa. For 
uncropped blots see Supplementary Data File. 
 
Figure 3 
Enhanced proteolysis of tau fibrils. (a) Tau fibrils were incubated with proteolytically 
active HTRA1 (wt HTRA1) after 2 h of preincubation with buffer (left panel), with 10 
fold molar excess of HTRA1 S328A compared to proteolytically active HTRA1 (right 
panel), or with 10 fold molar excess of the isolated PDZ domain of HTRA1 as control 
(bottom panel). Aliquots were taken before disintegration (-2 h) or at the indicated 
time points after adding wt HTRA1. (b) Repeated experiments with soluble tau. All 
samples were subjected to SDS-PAGE and silver staining (n=3). (c) Enhanced 
proteolysis after disintegration assessed by AFM. Tau fibrils were incubated with 
buffer, HTRA1 S328A (SA) or the PDZ domain (PDZ) of HTRA1 for 2 h before 
adding buffer (Ctrl) or active HTRA1 (WT HTRA1) and further incubation for 3 h. 
Protein concentrations and molar ratios were as in Fig. 3a. The quantification of the 
abundance of tau fibrils was done as in Fig. 1.  Scale bars, 0.5 µm. For representative 
images, see Supplementary Fig. 5b. Uncropped gel images are provided in a 
Supplementary Data File. 
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Figure 4 
Association of HTRA1 with fibrils and their proteolysis analyzed by single molecule 
approaches. (a) Negative-stain electron microscopy of HTRA1 S328A and tau fibrils. 
Fibrils were incubated with buffer (A), HTRA1 S328A at a molar ratio HTRA1:tau of 
1:1 (B) or 3:1 (C) for 20 min before glycerol gradient ultracentrifugation to separate 
soluble HTRA1 and tau from the fibrils. Representative images from the fractions 
containing fibrils are shown. The inlets show magnified sections indicating the width 
of the fibrils as vertical scale bars, i.e. 20 nm (A), 25 nm (B) and 30 nm (C). (b,c) 
Time-course of proteolysis of tau fibrils followed by TIRFM. DyLight488 labeled tau 
fibrils (0.01 µM) adhering to the glass bottom of microscopy slides were incubated 
with (b) buffer or (c) 1 µM wt HTRA1 for 10 h. Images were acquired every 2 h and 
displayed as single time points (bottom panels) to follow the continuous degradation 
of fibrils. The local fluorescence decrease is represented as the differences in pixel 
intensities between t0h and t10h, the values of which were translated into a spectrum 
LUT (top right). As reference, the respective image of the time point t0h is shown (top 
left). Scale bars, 5 µm. 
 
Figure 5 
Analysis of cleavage sites in tau. (a) Tau fibrils or (b) soluble tau were proteolyzed by 
wt HTRA1 for the indicated time points following preincubation for 2 h with buffer 
(orange bars) or a 10 fold molar excess of HTRA1 S328A (green bars). Peptidic 
cleavage products were analyzed by mass spectrometry. The identified cleavage sites 
were mapped to sections of the primary sequence of tau indicated at the x-axis of the 
graphs. The tightly packed core region of tau fibrils is highlighted in red. 
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Figure 6 
Fibril disintegration analyses using HTRA1 S328A and HTRA1 ∆PDZ S328A. (a) 
Sedimentation assays and (b) AFM measurements were done and analyzed as in Fig. 
1. For each condition, >50 individual fibrils recorded by AFM were included into 
statistical analyses. (c) Proteolytic degradation by wt HTRA1. Tau fibrils were 
proteolyzed by HTRA1 after preincubation with buffer, 10 x HTRA1 S328A, or 10x 
HTRA1 ∆PDZ S328A and analyzed as in Fig. 3. * indicates an autoproteolytic 
product of HTRA1.  Uncropped gel images are provided in a Supplementary Data 
File. (d) Mass-spectrometry as in Fig. 5 using peptidic cleavage products of 
proteolysis reactions from (c) (n=3). For statistical analysis, see Supplementary Table 
1. (e) Cell based assays done as in Fig. 2c. For uncropped blots see Supplementary 
Data File. (f) Binding of the tau peptide KTDHGAEIV (aa 385-393) to the PDZ 
domain of HTRA1 measured by ITC.  
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ONLINE METHODS 
Antibodies and chemicals 
Rabbit polyclonal antibodies against tau and mouse monoclonal antibodies against 
actin and HA-tag were obtained from Abcam (ab-64193), MP biomedicals (clone C4, 
#691001) and Covance (HA.11, clone 16B12, cat.no. MMS-101P), respectively. 
Polyclonal antibody against the HTRA1 PDZ domain (aa377-480)
266
 was made in-
house and tested for specificity as well as cross-reactivity with other HtrA family 
members (data not shown). The rabbit polyclonal antibody against residues 158-480 
of HTRA1 was a gift from A. Baldi
20
. The Aβ1-42 peptide was ordered from Designer 
BioScience, Cambridge, UK, tau peptides used in ITC binding assays were ordered 
from Intavis, Cologne. For immunofluorescence microscopy, secondary Alexa Fluor 
633 coupled goat anti-mouse and goat anti-rabbit antibodies were purchased from 
Life Technologies, as was the To-Pro 3 nuclear counterstain. The amine-reactive dye 
Alexa Fluor 568 carboxylic acid, succinimidyl ester, as well as fluorescently labeled 
secondary antibodies for immunofluorescence were purchased from Life 
Technologies. Amine-reactive DyLight488 antibody labeling kits were purchased 
from Thermo Scientific, glass-bottom slides for TIRFM by Ibidi (Martinsried, 
Germany). Thioflavin S, the protein transfection reagent Pro-Ject and MDH from 
porcine heart were ordered from AAT Bioquest, Thermo Fisher Scientific and Roche, 
respectively. Aldolase was taken from a gel filtration HMW calibration kit (GE 
Healthcare). 
 
Plasmids 
Bacterial expression plasmids based on the pET21d (Novagen) for purification of 
recombinant 6 x His – tagged HTRA1, ∆PDZ, HTRA1 S328A and S328A ∆PDZ 
were published previously
7
, the expression plasmid encoding the PDZ domain of 
HTRA1 with a C-terminal 6 x His – tag (aa 380-480) was constructed by PCR and 
standard cloning techniques using the above plasmid as template. 4R wt and MTBD 
tau plasmids were constructed by cloning the coding sequence of full-length 2N4R 
human tau (441 aa isoform) and of aa 258-360 containing the ∆K280 mutation into 
pET3d expression vectors (Novagen) using NcoI and BamHI restriction enzymes. The 
MTBD fragment was chosen because of its previously published high aggregation 
propensity
24
. For transient overexpression of HA-tagged full-length 4R tau with the 
P301L mutation, the respective coding sequence was amplified and cloned into 
pcDNA3.1 for constitutive overexpression in mammalian cultured cells, using a 
forward primer introducing an N-terminal HA tag with a BamHI restriction site and a 
reverse primer with an XhoI restriction site. 
 
Expression and purification of recombinant human HTRA1, full-length tau and 
MTBD of tau 
For the in vitro protease and disintegration assays and the treatment of cells with 
recombinant HTRA1, the indicated variants of human HTRA1 were purified as 
described previouslyʹ͸. After Ni-NTA affinity and hydroxyapatite chromatography 
with phosphate gradient elution, the protein was further purified by size exclusion 
chromatography using Superdex 200 preparation grade columns (GE Healthcare) in 
10 mM HEPES, 50 mM (NH4)2SO4, pH 7.5. Protein concentrations were determined 
by Bradford assays and SDS-PAGE. HTRA1, HTRA1 ∆PDZ and the PDZ domain 
comprise residues 158-480, 158-375 and 377-480, respectively. 4R wt tau and MTBD 
tau were purified as described previouslyʹ͸.  
 ʹͺ
 
Heparin induced fibrillization of recombinant human tau 
Aggregation of human full-length tau was performed as described previouslyʹ͸ with 
minor modifications. 20 µM tau was incubated in aggregation buffer (100 mM 
sodium acetate, 2 mM DTT, pH 7) at 55 °C, 800 rpm for 10 min, followed by 
addition of 1 mM fresh DTT and 50 µM heparin. After fibrillization at 37 °C, 
900 rpm for 48 h up to 5 days, with addition of 1 mM of fresh DTT every 24 – 48 h, 
the extent of aggregation was checked by ultracentrifugation and Thioflavin T 
fluorescence. The resulting aggregates were used in disintegration experiments as 
explained above. For the proteolysis experiments with HTRA1, the tau fibrils were 
sedimented by ultracentrifugation at 186,000 x g, 4 °C for 1 h and resuspended with 
HTRA1 proteolysis buffer in order to remove heparin and soluble tau species. 
Concentrations were determined by SDS-PAGE, Coomassie staining and comparison 
with BSA samples of known concentration. Fibrils composed of MTBD tau were 
assembled accordingly, except that the duration of fibrillization was reduced to 24 h. 
 
Protein labeling 
For immunofluorescence microscopy, recombinant human HTRA1 was labeled with 
the amine reactive fluorescent dye Alexa Fluor 568 carboxylic acid, succinimidyl 
ester (Life Technologies), by incubating 200 µM of HTRA1 with 2 mM of the 
reactive dye in 100 mM sodium bicarbonate, pH 8.3, at room temperature (RT) and 
constant agitation for 1 h. Prior to the labeling reaction, HTRA1 solution was adjusted 
to the labeling buffer using desalting columns (PD SpinTrap G-25, GE Healthcare). 
After completing the labeling reaction, the labeled protein was separated from the free 
dye using desalting columns and stored at -80 °C in single-use aliquots. For TIRFM 
of fibrils, tau fibrillization was performed as described above for 48 h, the fibrils were 
dialyzed against the labeling buffer PBS, pH 7.4, and incubated with 1/10 of the 
recommended amount of DyLight 488 amine-reactive dye from an antibody labeling 
kit (Thermo Scientific). Labeling buffer and the ratio of dye to protein were chosen to 
yield a low degree of labeling in order to preserve the fibril structure and minimize 
the interference of the label with the proteolysis by HTRA1. The labeling reaction 
was performed for 1 h at RT without agitation in the dark. The labeled fibrils were 
dialyzed against PBS, pH 7.4 to remove unbound dye and stored on ice in the dark 
until usage.  
 
Disintegration of tau fibrils by HTRA1 in vitro 
For disintegration assays by ultracentrifugation, 6.8 µM full-length or MTBD tau 
aggregates from 48 h or 24 h fibrillization reactions, respectively, were incubated 
with buffer or amounts of HTRA1 S328A corresponding to the indicated molar ratios 
or with control proteins in 100 mM piperazine-N,N′-bis(2-ethanesulfonic acid) 
(PIPES), 100 mM NaCl, 1 mM DTT, pH 7 at 37 °C, 450 rpm, for 16 h. The titration 
of HTRA1 was done in 100 mM 2-(N-morpholino)ethanesulfonic acid (MES), 
100 mM NaCl, 1 mM DTT, pH 6 for 1 h. Analysis of solubility was performed by 
ultracentrifugation of 20 µl samples at 186,000 x g, 4 °C for 1 h. As controls, HTRA1 
or the proteins indicated were incubated under the same conditions without tau, but 
with the respective volume of aggregation buffer (100 mM sodium acetate, 2 mM 
DTT, pH 7). The supernatants were mixed with loading buffer containing DTT, the 
pellets were solubilized with the respective amounts of loading buffer by thorough 
vortexing and resuspending. Total samples were removed before ultracentrifugation 
and treated accordingly. The amounts of tau in the individual fractions were assessed 
 ʹͻ
by SDS-PAGE followed by Coomassie staining. MTBD tau was detected by 
immunobloting with a polyclonal antibody against the repeat region of tau, whereas 
HTRA1 and control proteins were analyzed by Coomassie staining. The relative 
amounts of soluble Tau were determined by calculating the ratio of band intensities of 
the supernatant versus total protein samples using the ImageJ gel analysis plugin. For 
the titration experiments using varying concentrations of HTRA1, HTRA1 S328A 
was incubated with full-length tau fibrils at the indicated ratios for 1 h at 37°C 
followed by ultracentrifugation and SDS-PAGE as described above. Band intensities 
determined using the gel analyzing tool implemented in ImageJ of Coomassie stained 
gels of the supernatant samples were divided by the intensities of the total samples for 
the relative amount of solubilized tau shown in the graph. 4-8 independent 
experiments were used to calculate the mean and SEM of solubilized tau for each 
ratio. For AFM analysis, the disintegration was done using 100 mM MES, 100 mM 
NaCl, 1 mM DTT, pH 6 and the disintegration samples were diluted to 2 µM final tau 
concentration based on the full-length monomer molecular weight of 45.8 kDa.  
 
Preparation of Aβ1-42 aggregates and disintegration by HTRA1 S328A 
For the aggregation of the Aβ1-42 peptide, the lyophilized powder was dissolved in 
DMSO to obtain a 10 mM Aβ1-42  stock solution which was stored as 20 µl aliquots at 
-20°C. The aggregation was performed as described in the article text, by dilution of 
the Aβ1-42 peptide into aggregation buffer (50 mM Tris, 50 mM NaCl, 1 mM EDTA, 
pH 7.5) to a final concentration of 50 µM, followed by incubation without agitation at 
37°C for 14 h. The successful aggregation was assessed by means of ThT 
fluorescence and sedimentation by ultracentrifugation. Aβ1-42 disintegration was 
performed by incubation of 25 µM Aβ1-42 aggregates with equimolar amounts of 
HTRA1 S328A or MDH in 100 mM MES, 100 mM NaCl, pH 6 at 37 °C, 450 rpm for 
16 h. After the incubation period, the insolubility was determined by 
ultracentrifugation, followed by SDS-PAGE of a sample from the disintegration 
reaction, the supernatant and the pellet using pre-cast 4-12% Bis-Tris gels (Life 
Technologies). The protein bands were detected by silver staining. 
 
In vitro proteolysis of soluble and fibrillar tau 
Proteolysis of tau fibrils and soluble tau by HTRA1 was done essentially as described 
in the article text. 680 nM tau were incubated with wt HTRA1 at a molar 
protease:substrate ratio of 1:2.5, i.e., with 272 nM wt HTRA1 in 50 mM Tris/HCl, 
5 mM Tris(2-carboxyethyl)phosphine (TCEP), pH 8 at 37 °C, 350 rpm. Aliquots were 
taken at the indicated time points, mixed with loading dye and 50 mM TCEP, flash 
frozen in liquid nitrogen and kept frozen until analysis by SDS-PAGE. For 
disintegration followed by proteolysis, tau fibrils or soluble tau were incubated with a 
10 fold molar excess of HTRA1 S328A, S328A ∆PDZ or the PDZ domain as 
compared to wt HTRA1 (i.e., 2.72 µM) or buffer at 37 °C for 2 h before addition of 
wt HTRA1. Samples were boiled at 96 °C for 10 min and subjected to SDS-PAGE 
using pre-cast 10% Bis-Tris polyacrylamide gels (Life Technologies). For proteolysis 
followed by AFM, the same protocol was used except that 2 µM fibrillar tau was 
used, with the other protein concentrations adjusted accordingly to obtain the same 
molar ratios. Before AFM, the ultracentrifugation step was omitted in order to keep 
the fibrils intact for reliable analysis. 
 
AFM and image analysis 
 ͵Ͳ
Without previous treatment, 5 µl samples were deposited on a freshly cleaved mica 
surface (Plano GmbH) and adsorbed for 3 min at RT. After addition of 15 µl 1X 
TAEMg (40 mM Tris, 20 mM acetic acid, 2 mM EDTA, 12.5 mM Mg acetate, pH 8), 
the sample was scanned on a MultiModeTM 8 microscope (Bruker, Germany) 
equipped with a Nanoscope V controller, using the ScanAsyst® PeakForce 
TappingTM operational mode. Silicon nitride probes with 0.7 N/m nominal spring 
constant and sharpened pyramidal tips (ScanAsyst Fluid+, Bruker) were used for 
scanning. At least three images (3x3 µm) were acquired from random locations of the 
mica surface for statistical analysis of the results. Recorded views were 3rd order 
flattened and exported as TIFF files using the NanoScope 6.14 software (Bruker). 
Fibril lengths were analyzed with imageJ 
51
 by creating a collection of regions of 
interest (ROIs) corresponding to individual fibrils using the freehand selection tool 
and measuring the sets of ROIs of individual images. The sums of the lengths of 
fibrils in the images of each sample were statistically analyzed employing the two-
sided t-test for unpaired samples with Welch’s correction using the statistical analysis 
software Prism 5 (GraphPad). To detect possible changes in the abundance of fibrils 
depending on their individual lengths, the frequency distribution was analyzed with 
the same statistical software, using the data sets obtained as described above. The bin 
width for the distribution was set to 50 nm, and the distribution of lengths ranging 
from 0-1200 nm was displayed as absolute numbers or relative frequencies of fibrils 
populating each length interval. 
 
Negative-stain electron microscopy of tau fibrils bound by HTRA1 S328A 
Fibril decoration with HTRA1 and isolation. Before isolation via glycerol gradient 
ultracentrifugation and negative-stain EM, 12 µM tau fibrils were incubated in 300 µl 
50 mM Tris, pH 8, with HTRA1 at a molar ratio HTRA1:tau of 1:1 or 3:1 or with 
buffer at 37°C for 20 min. Glycerol gradients (10-40% (vol/vol)) were prepared using 
a gradient former (Gradient master 107, Biocomp). Subsequently, samples were 
added on the top of the gradients and were then centrifuged using a SW40-Ti rotor 
(Beckman Instruments) at 40,000 x g (i.e., 285,000 x g), 4°C, for 16 h. Fractions were 
harvested and analyzed by EM. 
Grid preparation and image recording. 4 µl sample droplets were applied to freshly 
glow-discharged grids (Agar scientific; G2400C) covered by a continuous thin carbon 
film. The sample was left for 45sec on the grid before blotting using filter paper 
(Whatman no. 4). The grid was then washed twice with ddH2O and negatively stained 
with 0.7% uranyl formate (Polysciences) for 45 sec. After blotting the grid was air-
dried and transferred to a JEOL JEM-1400 electron microscope equipped with a LaB6 
and operated at 120 kV. Digital micrographs were recorded with a 4k x 4k CMOS 
Camera F416 (TVIPS) using minimal dose conditions 
 
Total Internal Reflection Fluorescence Microscopy (TIRFM) of labeled fibrils 
Preparation of microscopy slides and image acquisition. For the visualization of the 
time-course of the proteolytic degradation of tau fibrils by HTRA1 using TIRF 
microscopy, heparin induced tau fibrils were labeled with a DyLight 488 fluorescent 
dye as described above. Sterile 8-well glass bottom microscopy slides (Ibidi, 
Martinsried, Germany) were coated with the labeled fibrils by incubation of 0.01 µM 
tau fibrils diluted in 50 mM Tris/HCl, pH 8, at 37°C protected from light for 1 h. 
After the coating reaction, the dishes were washed 3 x with PBS, pH 7.4 prior to the 
addition of 1 µM wt HTRA1 in 50 mM Tris/HCl, 5 mM TCEP, pH 8, or buffer alone. 
For the generation of movies, 120 images were recorded over a time period of 4 h, for 
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the quantification of the fluorescence decrease, higher resolution images were 
recorded every 2 h for a total of 10 h. To visualize the decrease in fluorescence 
irrespective of bleaching, the coated dishes were incubated with HTRA1 or buffer for 
14 h before recording single high resolution endpoint images. All TIRFM 
experiments were performed on an Eclipse Ti-E (Nikon) inverted microscope 
operated by the AndorIQ image acquisition software and equipped with an Andor 
AOTF Laser Combiner (Andor Technology), a motorized TIRF Illuminator Unit 
(Nikon) and a Clara Interline CCD camera (Andor Technology). The images were 
acquired using the 488 nm laser line and an Apo TIRF 100x/1.49NA oil-immersion 
objective (Nikon). 
Data processing. All image processing and quantification of the raw data acquired as 
described above was performed with ImageJ
51
. All time series of images were 
registered using the StackReg Pluginͷʹ and normalized to the same range of minimum 
and maximum displayed values prior to further analysis and processing. The movies 
were exported as .avi files at a frame-rate of 24 frames per second and JPEG 
compression. Regions of interest (ROIs) from the 10 h time series were displayed as a 
series of time points or used for the generation of fluorescence difference images. The 
latter were created by displaying the difference of the intensities of each pixel value 
between the t0h and t10h images as 8-bit images using the spectrum lookup table 
(LUT). For the analysis of local proteolysis depending on the relative position along 
the fibril length, 45 randomly chosen fibrils were analyzed with ImageJ. Single fibrils 
were marked with the freehand drawing tool, and their pixels were assigned to five 
portions of equal size corresponding to relative positions along the fibril. The 
fluorescence decrease in each portion relative to the total fluorescence decrease of the 
fibril was included in the data analysis. In order to quantify the changes in 
fluorescence of single fibrils as shown in Supplementary Fig. 6b, ROIs containing 
fibrils were generated by setting an intensity threshold for the t0h time point. This set 
of ROIs was applied to all time point images, and the average intensity of each ROI 
corresponding to a single fibril (or group of fibrils when overlapping) was normalized 
to the respective starting intensities at time point t0h. Each value shown corresponds to 
the mean value of 300-400 individual ROIs per sample. The single endpoint images 
were adjusted to equal intensity ranges and displayed as grayscale images or as 
images using the spectrum LUT for a more demonstrative visualization of 
fluorescence intensities. 
 
Mass spectrometry and analysis of cleavage sites 
Sample preparation for LC-MS. For the mass spectrometric analysis of cleavage sites 
by HTRA1, proteolysis of soluble tau and tau fibrils was performed for the indicated 
duration after 2 h preincubation with HTRA1 S328A or proteolysis buffer. Buffers 
and concentrations were the same as described above. 20 µl samples were acetone 
precipitated for 2 h at -80 °C. The supernatant containing the peptidic cleavage 
products was dried, resuspended with PBS and desalted as described
53
. 
LC-MS/MS. Experiments were performed on an Orbitrap Elite instrument (Thermo,
54
) 
that was coupled to an EASY-nLC 1000 liquid chromatography (LC) system 
(Thermo). The LC was operated in the one-column mode. The analytical column was 
a fused silica capillary (75 µm × 25 cm) with integrated PicoFrit emitter (New 
Objective) packed in-house with Reprosil-Pur 120 C18-AQ 3 µm resin (Dr. Maisch). 
The analytical column was encased by a column oven (Sonation) and attached to a 
nanospray flex ion source (Thermo). The column oven temperature was adjusted to 
45°C during data acquisition. Otherwise the temperature was kept at 30°C. The LC 
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was equipped with two mobile phases: solvent A (0.1% formic acid, FA, in UPLC 
grade water) and solvent B (0.1% FA in acetonitrile, ACN). Peptides were delivered 
directly to the analytical column via the integrated autosampler at a flow rate of 0.7-
0.9 µl/min in 100% solvent A. Peptides were subsequently eluted from the column by 
running a 25 min gradient of solvent A and solvent B (start with 2% B; gradient 2% to 
35% B for 10 min; gradient 35% to 45% B for 6 min; gradient 45% to 100% B for 2 
min; 100% B for 7 min) at a flow rate of 300 nl/min. 
The mass spectrometer was operated using Xcalibur software (version 2.2 SP1.48). 
The mass spectrometer was set in the positive ion mode. Precursor ion scanning was 
performed in the Orbitrap analyzer (FTMS) in the scan range of m/z 300-1,800 and at 
a resolution of 30,000 with the internal lock mass option turned on (lock mass was 
445.120025 m/z, polysiloxane)
55
. Product ion spectra were recorded in a data 
dependent fashion in the ion trap (ITMS) in a variable scan range and at a rapid 
normal scan rate. The ionization potential (spray voltage) was set to 1.6 – 2.0 kV. 
Peptides were analyzed using a repeating cycle consisting of a full precursor ion scan 
(1.0 × 10
6
 ions) followed by seven product ion scans (1.0 × 10
4
 ions) where peptides 
are isolated based on their intensity in the full survey scan (threshold of 500 counts) 
for tandem mass spectrum (MS2) generation that permits peptide sequencing and 
identification. CID collision energy was set to 35% for the generation of MS2 spectra. 
During MS2 data acquisition dynamic ion exclusion was set to 60 seconds with a 
maximum list of excluded ions consisting of 500 members and a repeat count of one. 
Ion injection time prediction, preview mode for the FTMS, monoisotopic precursor 
selection and charge state screening were enabled. Only charge states bigger than 1 
were considered for fragmentation. 
Peptide and Protein Identification. The recorded RAW files were processed in 
ProteomDiscoverer 1.3 (PD13, Thermo). MS2 spectra were extracted using the 
Spectrum Selector node. Precursor selection was set to “use MS1 precursor”. The 
mass range was set between 350 – 5,000 Da with a minimum peak count of 1. Mass 
analyzer was set to “any” and MS order to “MS2”. Activation type was set to “is 
CID” and Scan type was defined as “full” with ionization source set to “is 
nanospray”. Selected spectra were submitted to the in house MASCOT server 
(version 2.4.1
56
) using the PD13 MASCOT node. MS2 spectra data were searched 
against an E. coli K12 reference protein database downloaded from Uniprot 
(www.uniprot.org/ taxonomy/complete-proteomes, 4,312 protein sequences, 
download date 25.10.2013) and concatenated with the contaminants database (as 
implemented in MASCOT, 263 sequences) and the sequences of interest for Tau and 
HtrA1. The contaminants database contains known MS and was included to estimate 
the level of contamination. Mascot searches allowed for oxidation of methionine 
residues (16 Da) but no static modifications (cysteine residues were not alkylated with 
iodoacetamide). In accordance with our aim to detect endogenous cleavage sites no 
enzyme was specified. The instrument type was set to ESI-TRAP and the mass 
tolerance was set to ±5 ppm for precursor mass and ±0.5 Da for product ion masses. 
MS2 spectra matches were then evaluated using the peptide validation node of PD13 
with the standard settings (search against decoy database, target false discovery rate 
(FDR, strict): 0.01 and target FDR (released): 0.05). The reported results were further 
filtered. On peptide level only peptides with a minimum confidence ‘medium’ were 
reported and on protein level only proteins with a minimum of at least two peptide 
hits were reported. 
Data processing and P-site mapping. For data processing peptide lists were directly 
downloaded from MASCOT as CSV files. Prior to the download peptides were 
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filtered based on their peptide score. Only peptides with a stringent score >29 were 
accepted (identity threshold). The downloaded files were then further processed with 
several in-house developed PERL scripts. First the CSV files were converted to plain 
text files using the script MASCOT_Datacon_v05.pl. The obtained text files were 
then batch processed with the script SVG_builder_FAK_0555_script_v11.pl. 
Basically this script goes through all indicated peptide lists and records occurrences of 
peptides in each individual experiment. Also it calculates the start and end position of 
each peptide in an identified protein match and records the number of peptide 
spectrum matches (PSM) irrespective of any modifications (count is based only on 
amino acid sequence). The recorded peptides were mapped to the primary sequence of 
full-length 4R tau, and the P1 sites were derived from their N- and C-terminal 
residues. Assignment of the cleavage site to equal sized sections of the tau primary 
sequence was done with Excel (Microsoft).  
 
Isothermal titration calorimetry (ITC) 
To detect the direct interaction between HTRA1, HTRA1 ∆PDZ or the isolated PDZ 
domain of HTRA1 with tau derived peptides, the indicated proteins were dialyzed 
against 50 mM Tris, 150 mM NaCl, pH 8 or 100 mM NaH2PO4, 150 mM NaCl, 
pH 7.2. The peptides were dissolved in the same buffer but with 2% DMSO to a final 
concentration of 2 mM. The measurements were performed with a MicroCal ITC200 
(Malvern Instruments) with 2 mM peptide in the syringe and 20 µM or 40 µM protein 
as indicated in the sample cell. For each measurement, 20 injections á 2 µl were done, 
except for the first 0.8 µl injection, at 37°C with a stirring speed of 750 rpm. To 
exclude dilution effects, control measurements using peptide injections into buffer or 
buffer injections into the sample cells containing HTRA1 were performed. The raw 
data was evaluated using the MicroCal Origin software and applying the one set of 
sites fitting mode according to the instructions of the manufacturer. 
 
Internalization of recombinant HTRA1 by 293T HEK cells 
Given that HTRA1 is secreted into the cell culture medium but also located to the 
cytosol, we reasoned that this subfraction of HTRA1 could be reinternalized after 
secretion. To study the spontaneous internalization of recombinant HTRA1 protein 
from the medium, 8 x 10
5
 293T HEK cells were seeded in poly-D-lysine coated 6 cm 
cell culture dishes and grown for 24 h to reach 50-60% confluency. Cells were 
washed twice with PBS before addition of 4 ml serum-free medium containing 
recombinant, labeled HTRA1 in the concentration and for the incubation time 
indicated. Subsequently, cells were detached from the culture dish by trypsin / EDTA 
treatment, centrifuged, and the cell pellet was washed thoroughly with PBS to remove 
all residual trypsin from the sample. The resulting pellet was lyzed with RIPA buffer 
containing protease inhibitor (Roche). 150 µg total cell lysate were analyzed by SDS 
PAGE followed by immunoblotting. Alternatively, 1.5 x 10
5
 cells were seeded in each 
well of a 24 well plate on poly-D-lysine coated glass coverslips, treated with 500 µl 
serum-free DMEM medium per well containing 50 µg/ml Alexa Fluor 568 labeled 
HTRA1 S328A, grown for 24 h, washed, methanol fixed and stained for 
immunofluorescence as described above. As a control for the uptake of labeled 
HTRA1, the amine reactive dye by itself was saturated by 1:5 dilution with 100 mM 
Tris, pH 8.42, and the same concentration as assessed by absorption at λ = 578 nm of 
the labeled protein and isolated dye was used.  
 
Seeding of tau aggregation in 293T HEK cells 
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The seeding of intracellular tau aggregation in 293T HEK cells was done as 
described͵Ͳ with some modifications and the additional analysis of the effect of 
HTRA1 internalized from the extracellular space. 293T HEK cells were used, as this 
cells line is suitable for particularly high expression, which is needed for efficient 
seeding of cytoplasmic tau aggregation. Cell lines are routinely tested for 
mycoplasma contaminations on a regular basis in the lab. 
Preparation of MTBD aggregate seeds. Fibril seeds composed of MTBD tau were 
prepared by fibrillization for 24 h as described above, followed by ultracentrifugation 
at 186,000 x g, 4 °C for 1 h. The pellets were thoroughly resuspended with PBS, 
pH 7.4, vortexed, and the extent of fibrillization was checked by SDS-PAGE of 
samples from the supernatant and pellet. Typically, all of the MTBD tau was found in 
the pellet after 24 h of fibrillization. MTBD tau aggregates were sonicated in a water 
bath for 2 x 2 min before performing protein transfection. 
Transient transfection of 293T HEK cells and seeding of aggregation. For sarkosyl 
extraction experiments, 293T HEK cells were transiently transfected by nucleofection 
(Lonza, Switzerland) with a pcDNA3.1 plasmid for overexpression of HA-tagged 
full-length human tau with the point mutation P301L. 4 x 10
5
 cells were grown in 
each well of a 6-well plate for expression of P301L tau for 24 h to reach about 50% 
confluency. Cell culture dishes were poly-L-lysine coated prior to seeding. Freshly 
prepared MTBD tau aggregate seeds were transfected into the cells at a final 
concentration of 17.5 µg/ml using 10 µl per well of the cationic lipid based protein 
transfection reagent Pro-Ject, followed by 4 h incubation with DMEM culture 
medium without serum and 20 h of incubation with 0.5% fetal bovine serum (FBS). 
For HTRA1 internalization experiments, cells were washed twice with serum-free 
DMEM medium, followed by addition of 2 ml of medium conditioned with either 
PBS or HTRA1 at a final concentration of 150 µg/ml, i.e. 4.1 µM, and incubated at 
37 °C for 20 h before performing sarkosyl extraction and immunoblotting.  
Sarkosyl extraction from cultured cells. After seeded aggregation, sarkosyl extraction 
was performed to assess the abundance of aggregated versus soluble, HA-tagged 
P301L tau. Sarkosyl extraction was done essentially as described before 
30
 with some 
modifications. Cells were detached from the culture dish by trypsinization and 
washed thoroughly with PBS to remove all residual trypsin from the cell pellet. The 
pellet was resuspended with lysis buffer containing sarkosyl, 10 mM Tris/HCl, 
150 mM NaCl, 1 mM EGTA, 5 mM EDTA, 1% sarkosyl, pH 7.4 with protease 
inhibitor (Roche complete protease inhibitor tablet), and incubated on ice for 15 min. 
For cell lysis, the suspension was 10 x syringe sheared with a 27G needle, followed 
by incubation on ice for 15 min, 2 x 2 min sonication in the water bath and incubation 
at 25 °C for 20 min. The samples were ultracentrifuged at 186,000 x g, 4 °C for 
60 min, the supernatant was saved as sarkosyl soluble fraction, the pellet was 
resuspended with the corresponding amount of SDS loading buffer containing 1% 
SDS by vigorous vortexing. Equal amounts of the individual samples were subjected 
to SDS-PAGE and immunoblotting based on the sarkosyl supernatant concentrations 
determined by absorption at 280 nm using a NanoDrop micro volume 
spectrophotometer (Peqlab, Germany). Volumes of the sarkosyl insoluble fractions 
were adjusted accordingly. The samples were loaded onto 10% SDS gels followed by 
immunoblotting against tau, the HA-tag, HTRA1 or actin. The bands were detected 
by alkaline phosphatase (AP) coupled secondary antibodies, followed by 
chromogenic detection of AP activity. For quantification, blots from 3-4 independent 
experiments were used to calculate the signal intensities of Sarkosyl pellet bands from 
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HTRA1 treated samples relative to the PBS treated samples, using the gel analysis 
tool implemented in ImageJ. 
 
Immunofluorescence and confocal laser-scanning microscopy 
For seeding of tau aggregation and HTRA1 internalization experiments to be analyzed 
by confocal laser-scanning microscopy, the cells were transfected as done before for 
sarkosyl extraction except some modifications. Following transfection with tau P301L 
expression plasmids, 1.6 x 10
5
 cells were transferred to each well of 24 well plates 
with poly-D-lysine coated glass coverslips and grown for 24 h before transfection 
with MTBD seeds which were prepared as described above. For transfection in 24 
well plates, 2.5 µl of the transfection reagent were used per well. Where indicated, 
treatment with labeled HTRA1 was done as described above except that 1.35 µM 
labeled HTRA1 was used in a final volume of 500 µl. After an incubation period of 
20 h as described above, cells were fixed with ice-cold methanol, permeabilized with 
0.5% Triton X-100 for 5 min, and washed with PBS before further staining was 
performed. For the detection of amyloid aggregates, Thioflavin S (ThS) staining was 
performed as described in the article text, by incubation with 0.005% ThS, dissolved 
in PBS and sterile filtered, for 8 min at RT, followed by 5 x washing with 50% 
ethanol for 5 min. The samples were then blocked with 5% bovine serum albumin 
(BSA) for 30 min before antibody staining was done with primary antibodies as 
indicated, using Alexa Fluor 633 labeled secondary antibodies. The anti HA antibody 
and secondary antibodies were diluted 1:500, the polyclonal anti HTRA1 PDZ 
antibody was used in 1:50 dilution in 3% BSA/PBS. Before mounting the samples 
with ProLong Gold antifade mounting solution (Life Technologies), they were 
washed with PBS 3 x for 15 min at RT. DAPI was added in 1:10,000 dilution together 
with the secondary antibody solutions. The nuclear counterstain To-Pro 3 iodide (Life 
Technologies) was used diluted 1:500 from a 1 mM stock solution. When To-Pro 3 
staining was done, the samples were treated with 100 µg/ml RNAse A at 37 °C for 
20 min to eliminate unspecific staining of cytoplasmic RNA. Microscopy was done 
with a Leica TCS SP5 Confocal Laser Scanning Microscope equipped with Leica 
HyD Gallium Arsenide phosphide hybrid detection systems. Image acquisition was 
performed with the same detector sensitivity settings for samples and controls. Images 
of the different channels were acquired individually in serial acquisition mode to 
avoid fluorescent bleed-through. Images of single focal planes using 60 µm pinhole 
width are shown.  
 
 
ONLINE METHODS REFERENCES 
51. Schneider, C.A., Rasband, W.S. & Eliceiri, K.W. NIH Image to ImageJ: 25 
years of image analysis. Nat. Methods 9, 671-675 (2012). 
52. Thevenaz, P., Ruttimann, U.E. & Unser, M. A pyramid approach to subpixel 
registration based on intensity. IEEE Trans. Image Process 7, 27-41 (1998). 
53. Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, 
enrichment, pre-fractionation and storage of peptides for proteomics using 
StageTips. Nat. Protoc. 2, 1896-1906 (2007). 
54. Michalski, A. et al. Ultra high resolution linear ion trap Orbitrap mass 
spectrometer (Orbitrap Elite) facilitates top down LC MS/MS and versatile 
peptide fragmentation modes. Mol. Cell. Proteomics 11, O111 013698 (2012). 
 ͵͸
55. Olsen, J.V. et al. Parts per million mass accuracy on an Orbitrap mass 
spectrometer via lock mass injection into a C-trap. Mol. Cell. Proteomics 4, 
2010-2021 (2005). 
56. Perkins, D.N., Pappin, D.J., Creasy, D.M. & Cottrell, J.S. Probability-based 
protein identification by searching sequence databases using mass 
spectrometry data. Electrophoresis 20, 3551-3567 (1999). 
 
 
  
 ͵͹
 
Competing financial interests statement 
There are no competing financial interests 
 
 







  1 
Supplementary Information 
 
 
Determinants of amyloid fibril degradation by the PDZ protease HTRA1 
 
Simon Pöpsel1, Andreas Sprengel1, Barbara Sacca1, Farnusch Kaschani1, Markus 
Kaiser1, Tim Clausen2 and Michael Ehrmann1,3 * 
1 Centre for Medical Biotechnology, Faculty of Biology, University Duisburg-Essen, 
Universitaetsstrasse, 45141 Essen, Germany 
2 Research Institute of Molecular Pathology – IMP, Dr. Bohrgasse 7, A-1030 Vienna, 
Austria 
3 School of Biosciences, Cardiff University, Cardiff CF10 3US, UK 
 
* Corresponding author: 
Email: michael.ehrmann@uni‐due.de, Phone: +49-201-183 2949 
 
Running title: Proteolysis of amyloid fibrils by HTRA1 
 
  
  2 
Supplementary Results 
 
 
Supplementary Table 1 
 
Fibrils A B C D E F G H 
wt HTRA1  
+ HTRA1 S328A 
n/a 0.139 
n.s. 
n/a n/a 0.048 
* 
0.016 
* 
0.028 
* 
0.13 
n.s. 
wt HTRA1  
+ HTRA1 ∆PDZ S328A 
n/a 1 
n.s. 
n/a n/a 0.003 
** 
0.138 
n.s. 
0.519 
n.s. 
0.26 
n.s. 
 
Soluble Tau A B C D E F G H 
wt HTRA1  
+ HTRA1 S328A 
1 
n.s. 
0.028 
* 
0.37 
n.s. 
1 
n.s. 
0.42 
n.s. 
0.31 
n.s. 
n/a 0.37 
n.s. 
wt HTRA1  
+ HTRA1 ∆PDZ S328A 
1 
n.s. 
0.044 
* 
0.35 
n.s. 
n/a 0.37 
n.s. 
0.57 
n.s. 
n/a 0.37 
n.s. 
 
Statistical analysis of the number of cleavage sites in tau fibrils or soluble tau. p-values of 
wt HTRA1 vs. (wt HTRA1 + HTRA1 S328A) and of wt HTRA1vs. (wt HTRA1 + HTRA1 
∆PDZ S328A). The number of cleavage sites in fibrils or soluble tau by wt HTRA1 were 
compared with the respective numbers after incubation with HTRA1 S328A and HTRA1 
∆PDZ S328A as shown in Fig. 6d, using a two-tailed t-test for unpaired samples with 
Welch’s correction for unequal variances in GraphPad Prism. n.s. = not significant, * = p < 
0.05, ** = p < 0.01, n/a = not applicable. n = three independent experiments. 
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Supplementary Figures 
 
Supplementary Figure 1 
(a), (b) Quantification of fibril disintegration by HTRA1 S328A. (a) Quantification of band 
intensities and analysis of the ratio of soluble versus total tau (n=4).  p-values are according 
to a two-sided t-test for unpaired datasets with Welch’s correction for unequal variances. (b) 
Titration of HTRA1 S328A in sedimentation assay. Tau fibrils were incubated with HTRA1 
at the indicated molar ratios, followed by ultracentrifugation. Solubilization of fibrils was 
quantified as the ratio of soluble versus total tau. Data points represent the mean of 4-8 
independent assays, error bars are SEM. (c), (d)Sedimentation assay of MTBD tau fibrils. (c) 
6.7 µM MTBD tau fibrils were incubated with a 3 fold molar excess of proteolytically 
inactive HTRA1 S328A (HTRA1 SA) or Aldolase at 37°C for 16 h followed by 
ultracentrifugation. Subsequently, samples before centrifugation (T, total), of pellet (P) and 
supernatant (S) fractions were subjected to SDS-PAGE followed by immunoblotting against 
the repeat region of tau. The samples were subjected to SDS-PAGE followed by Coomassie 
staining to detect HTRA1 and control protein in the presence of MTBD fibrils (middle panel) 
or after incubation without tau as a control (bottom panel). (d) Quantification of MTBD 
solubilization based on the band intensities of soluble versus total tau samples in the blots 
shown in (c). The indicated p-values were computed with a two-sided t-test for unpaired 
samples with Welch’s correction for unequal variances in GraphPad Prism. 
 
Supplementary Figure 2 
 (a), (b) Quantification of AFM analysis of fibril disintegration. Quantification of fibril 
abundance based on image analysis of 4 random 3 x 3 µm views per sample. Fibrils were 
treated with HTRA1 S328A or the isolated PDZ domain of HTRA1 as shown in Fig. 1, b and 
c. Columns represent the mean of total fibril lengths per view. Error bars are SEM. p-values 
indicate statistical significance according to a two-sided t-test for unpaired datasets with 
Welch’s correction. For each condition > 100 individual fibrils were included into statistical 
analyses.  (c)  Distribution of fibril size after disintegration by HTRA1 S328A. The lengths of 
individual tau fibrils were measured in at least 3-4 individual regions of samples as described 
in Fig. 1. The distribution of fibril size was assessed by means of a frequency distribution 
using a bin width, i.e. the length intervals to be analyzed, of 50 nm. The relative frequency of 
fibrils in the respective length intervals was plotted. The displayed lengths were limited to < 
1200 nm because only a minor number of fibrils exceeded this value.  
 
Supplementary Figure 3 
Internalization of recombinant HTRA1 by cultured 293T HEK cells. Cells were incubated for 
6 h with culture medium conditioned with increasing concentrations of HTRA1 (a) or with a 
fixed amount of HTRA1 (150 µg/ml = 4.1 µM) for the incubation times indicated (b). 
Lysates of trypsinized cells were subjected to SDS-PAGE and immunoblotting using 
antibodies against HTRA1 and Actin (loading control). As controls, cells were treated with 
PBS or 4.1 µM HTRA1 followed by incubation at 4°C for 6 h. (c-d) Uptake of fluorescently 
labeled HTRA1 S328A by 293T HEK cells followed by confocal microscopy. Cells were 
treated with 50 µg/ml (= 1.35 µM) HTRA1 or PBS (control) for 16 h, followed by methanol 
fixation and immunostaining against HTRA1 (c) or the HA tag (d) of transiently 
overexpressed tau as indicated. DAPI was used as nuclear counterstain. The images show the 
dispersed cytoplasmic or vesicular localization of internalized HTRA1 S328A (labeled with 
AF 568) (c) and positive immunostaining of HTRA1 and colocalization with its native 
cytoplasmic substrate tau (αHA antibody) (d). (e) Secondary antibody (2°AB) control of 
internalized, fluorescently labeled HTRA1. 293T HEK cells were treated with HTRA1 
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conditioned medium for 20 h, followed by fixation and staining as described above except 
for the primary antibody against HTRA1 being omitted in order to exclude unspecific 
staining of labeled HTRA1 or the AlexaFluor 568 dye by the secondary antibody. Scale bars, 
25 µm. The data are representative of at least 2 biological replicates. 
 
Supplementary Figure 4 
Cell based assay of fibril degradation by HTRA1. (a) Analysis of the amount of sarkosyl 
insoluble tau in the HTRA1 S328A treated cells relative to the PBS controls (n=4) Error bar 
is SEM. p-values were calculated with GraphPad Prism using a to a two-tailed, paired t-test. 
(b) 293T HEK cells were treated as described in Fig. 2. After seeding, cells were treated with 
culture medium conditioned with proteolytically active HTRA1 (wt) (4.1 µM) or PBS for 
20 h followed by lysis, sarkosyl extraction and immunoblotting of sarkosyl soluble (left 
panel) and insoluble (pellet, right panel) fractions against tau, and immunoblotting of the 
sarkosyl soluble fractions against HTRA1 to detect the uptake of recombinant wt HTRA1 
(lower left panel). Lower right panel: Analysis of the amount of Sarkosyl insoluble tau in the 
wt HTRA1 treated cells relative to the PBS controls. Data from 3 independent experiments, 
error bar represents the SEM. Decrease is highly significant according to a two-tailed, paired 
t-test, computed with GraphPad Prism. 
 
Supplementary Figure 5 
 (a) Tau fibrils (left) or soluble tau (right) were proteolyzed by wt HTRA1 present in the 
concentration corresponding to HTRA1 S328A in Fig. 3 (a) and (b). Samples were treated as 
described in Fig. 3 and subjected to SDS-PAGE and silver staining (n=3). (b) Representative 
images of AFM analysis of Tau proteolysis by wt HTRA1 following incubation with buffer 
(top right), HTRA1 S328A (bottom left) or the isolated PDZ domain of HTRA1 (bottom 
right) as compared to the control incubated without wt HTRA1 (top left). (c) Distribution of 
fibril lengths after disintegration and proteolysis by HTRA1. Changes in the abundance of 
fibrils depending on their lengths were analyzed as described for the AFM data of 
disintegrated fibrils (Fig. 1b,c and Supplementary Fig. 2). The distribution of fibril lengths is 
shown as the relative frequency to assess changes in the lengths of fibrils.   
 
Supplementary Figure 6  
Proteolysis of labeled tau fibrils observed by TIRFM. (a) Decrease in fluorescence was 
analyzed with respect to the relative position along single fibrils to quantify the distribution 
of the total fluorescence decrease. Error bars are SEM. Scale bars, 5 µm. The data is 
representative of 2 biological and at least 4 technical replicates. (b) Decrease in the 
fluorescence intensity of individual fibrils in the buffer control (black circles) and in the 
presence of HTRA1 (green squares) as measured by TIRF microscopy. The values shown are 
the means of intensities relative to the fluorescence measured at t0h of 300-400 ROIs 
representing single or overlapping fibrils for each time point and sample as described. The 
data used originated from a single dataset. The error bars indicate the standard deviation. The 
total decrease in fluorescence was 29% in the buffer control versus 68% in the presence of 
wt HTRA1. (c) Representative endpoint images after 14 h of incubation of tau fibrils with 
buffer (top row) or 1 µM wt HTRA1 (bottom row) to illustrate the decreased fluorescence 
caused by the proteolysis of fibrils by HTRA1 irrespective of photobleaching. The images 
are shown with a spectrum LUT (left) for the visualization of the pixel intensities and as 
greyscale images for overview (middle). In the right panels, the regions highlighted by white 
boxes are zoomed in. Scale bars, 25 µm and 10 µm for overview and zoomed-in images, 
respectively. Representative images of 3 independent experiments are shown. 
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Supplementary Figure 7 
K
D
 of tau Peptides Determined by ITC. (Top panel) Representative ITC raw data and the 
binding isotherm based on the integrated heat changes are shown in the top and bottom part 
of the figure, respectively. The exemplary data represent the measurement of the peptide 
KTDHGAEIV corresponding to aa 385-393 of 4R tau. (Bottom panel) List of peptide 
sequences, their position within the aa sequence of tau and the KDs measured by ITC. 
Numbers correspond to µM values. For the ITC measurements, 2 µl of a 2 mM solution of 
the respective peptides were injected into the sample cell containing 20 µM HTRA1. The 
area under each peak was integrated and plotted against the molar ratio peptide/HTRA1 in 
the sample cell. The black line represents the fit to a binding isotherm according to the one 
set of sites fitting mode. n.d. = not detected (no binding). 
  
Supplementary Figure 8  
Representative images of fibrils disintegration by HTRA1 S328A versus HTRA1 ΔPDZ 
S328A as analyzed by sedimentation (a) or AFM (b) assays as in Fig. 1. (c) Sedimentation 
Assay with MTBD Aggregates and HTRA1 ∆PDZ S328A. Sedimentation assays were 
performed as in Supplementary Fig. 1, except that in addition to buffer control and HTRA1 
S328A, HTRA1 ∆PDZ S328A and the isolated, recombinant PDZ domain were used. Top 
panel represents anti-tau immunoblots to visualize the MTBD of tau in the total (T), pellet 
(P) and supernatant (S) fractions. The middle and bottom panels show Coomassie stained 
gels of the reaction with and without MTBD tau to illustrate the solubility of the proteins 
added to tau. (d) Quantification of the band intensities of 4 independent experiments with the 
mean and SEM are shown. The indicated p-values were calculated according to a two-tailed 
t-test for unpaired datasets with Welch’s correction for unequal variances in GraphPad Prism. 
(e) Analysis of the amount of sarkosyl insoluble tau in HTRA1 S328A and HTRA1 ∆PDZ 
S328A treated cells relative to the PBS controls (n=4). Error bars are SEM. p values were 
computed with GraphPad Prism using a two-tailed, paired t-test. 
 
Supplementary Figure 9 
Disintegration of Aβ1-42 Aggregates by HTRA1 S328A. 50 µM Aβ1-42 (Aβ) were incubated 
with equimolar amounts of HTRA1 S328A or the control protein MDH, followed by 
ultracentrifugation and the analysis of samples from the disintegration reaction (T, total), the 
pellet (P) and supernatant (S) by SDS-PAGE and silver staining. The data are representative 
of 3 independent experiments.  
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Supplementary videos 
 
Supplementary Video 1 TIRF microscopy of fibril degradation. Fluorescently labeled tau 
fibrils adhering to microscopy slides were incubated with wt HTRA1. Proteolytic 
degradation of fibrils was followed by recording 120 images over a period of 4 h. 
 
Supplementary Video 2 TIRF microscopy of tau fibrils. To detect photobleaching, imaging 
of tau fibrils was performed in the absence of HTRA1 as described in Supplementary Video 
1. 
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